Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Selective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice. Aims: To investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder. Method: Patients with generalised social anxiety disorder were randomised to receive placebo (n=177) or 10–20 mg escitalopram (n=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score. Results: The study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P < 0.0 1). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment. Conclusions: Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
WITTCHEN, H.-U., STEIN, M. B., & KESSLER, R. C. (1999) · Psychological Medicine · doi:10.1017/s0033291798008174 · Cited by 745 · cited 1×
“Social phobia or anxiety disorder is increasingly recognised as a highly prevalent and chronic disorder with onset during the teenage years (Lepine & Pelissolo, 1996;´ ´ Wittchen et al, 1999).”
Background
Cited by
Stein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Self-citationKatzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Escitalopram [430-432] 1 Clomipramine [458,459] 3”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationSheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Metadata
- Authors
- Kasper, S., Stein, D. J., Loft, H., & Nil, R.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2005-03
- Volume
- 186
- Issue
- 3
- Pages
- 222-226
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2180149895
- Cited by
- 125
- References
- 2
- FWCI
- 20.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. https://app.cochat.ai/papers/10.1192/bjp.186.3.222
- The paper
- Kasper, S., Stein, D. J., Loft, H., & Nil, R. (2005). Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. British Journal of Psychiatry. https://doi.org/10.1192/bjp.186.3.222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.